AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
bethanechol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 358 | 674-38-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 45 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 14.53 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 625.41 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 46 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,GRK2 | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 12, 1948 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Peritonitis | 40.92 | 25.90 | 14 | 1293 | 19691 | 90607449 |
| Fall | 27.22 | 25.90 | 34 | 1273 | 481776 | 90145364 |
| Hypertensive nephropathy | 26.21 | 25.90 | 5 | 1302 | 673 | 90626467 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Potentiating drug interaction | 72.08 | 24.83 | 18 | 792 | 6450 | 42614075 |
| Oesophageal rupture | 60.62 | 24.83 | 10 | 800 | 444 | 42620081 |
| Urinary tract infection | 44.45 | 24.83 | 26 | 784 | 99258 | 42521267 |
| Pancreatic failure | 28.07 | 24.83 | 6 | 804 | 1081 | 42619444 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Potentiating drug interaction | 62.56 | 21.83 | 18 | 1960 | 11625 | 110575696 |
| Oesophageal rupture | 54.17 | 21.83 | 10 | 1968 | 907 | 110586414 |
| Urinary tract infection | 39.30 | 21.83 | 38 | 1940 | 326244 | 110261077 |
| Peritonitis | 31.13 | 21.83 | 14 | 1964 | 32593 | 110554728 |
| Infective pulmonary exacerbation of cystic fibrosis | 30.31 | 21.83 | 11 | 1967 | 14760 | 110572561 |
| Pancreatic failure | 23.81 | 21.83 | 6 | 1972 | 2348 | 110584973 |
| Hypertensive nephropathy | 23.00 | 21.83 | 5 | 1973 | 1033 | 110586288 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07AB02 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Choline esters |
| FDA MoA | N0000000104 | Cholinergic Muscarinic Agonists |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38325 | muscarinic agonist |
| FDA EPC | N0000175840 | Cholinergic Muscarinic Agonist |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D018721 | Muscarinic Agonists |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Retention of urine | indication | 267064002 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Irritable bowel syndrome | contraindication | 10743008 | DOID:9778 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Increased gastric tonus | contraindication | 18644006 | |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Parkinsonism | contraindication | 32798002 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Low blood pressure | contraindication | 45007003 | |
| Peritonitis | contraindication | 48661000 | |
| Bradycardia | contraindication | 48867003 | |
| Parkinson's disease | contraindication | 49049000 | DOID:14330 |
| Abnormal vasomotor function | contraindication | 70670009 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Atrioventricular block | contraindication | 233917008 | DOID:0050820 |
| Anastomosis of intestine | contraindication | 235407009 | |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Operation on gastrointestinal tract | contraindication | 386621005 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Bladder Surgery | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | GPCR | AGONIST | Ki | 4 | IUPHAR | CHEMBL | |||
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | Ki | 4.20 | IUPHAR | CHEMBL | |||
| Muscarinic acetylcholine receptor M1 | GPCR | AGONIST | Ki | 4 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | AGONIST | Ki | 4 | IUPHAR | ||||
| Muscarinic acetylcholine receptor | GPCR | Kd | 4.90 | CHEMBL | |||||
| Muscarinic receptor 2 | GPCR | EC50 | 6 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019634 | VUID |
| N0000147727 | NUI |
| D01000 | KEGG_DRUG |
| 590-63-6 | SECONDARY_CAS_RN |
| 19257 | RXNORM |
| C0053526 | UMLSCUI |
| CHEBI:3084 | CHEBI |
| CHEMBL1482 | ChEMBL_ID |
| DB01019 | DRUGBANK_ID |
| CHEMBL1768 | ChEMBL_ID |
| D018723 | MESH_DESCRIPTOR_UI |
| 2370 | PUBCHEM_CID |
| 297 | IUPHAR_LIGAND_ID |
| 004F72P8F4 | UNII |
| 3310 | MMSL |
| 4281 | MMSL |
| d01427 | MMSL |
| 4017938 | VANDF |
| 4019634 | VANDF |
| 001691 | NDDF |
| 004683 | NDDF |
| 31178001 | SNOMEDCT_US |
| 31690003 | SNOMEDCT_US |
| 372698003 | SNOMEDCT_US |
| 004F72P8F4 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0510 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0511 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0512 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0513 | TABLET | 50 mg | ORAL | ANDA | 19 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-516 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-517 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-518 | TABLET | 50 mg | ORAL | ANDA | 18 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-934 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-935 | TABLET | 10 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-936 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-937 | TABLET | 50 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-571 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-572 | TABLET | 10 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-573 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-574 | TABLET | 50 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-1624 | TABLET | 10 mg | ORAL | ANDA | 11 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-1625 | TABLET | 25 mg | ORAL | ANDA | 11 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5154 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-965 | TABLET | 5 mg | ORAL | ANDA | 15 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-966 | TABLET | 10 mg | ORAL | ANDA | 15 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-967 | TABLET | 25 mg | ORAL | ANDA | 15 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-968 | TABLET | 50 mg | ORAL | ANDA | 15 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-689 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-700 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-755 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-756 | TABLET | 10 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-757 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-758 | TABLET | 50 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-571 | TABLET | 5 mg | ORAL | ANDA | 10 sections |
| Bethanechol Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-572 | TABLET | 10 mg | ORAL | ANDA | 10 sections |